From the Research
No, Combivent is no longer available as an HFA inhaler in the United States. Combivent Respimat, a soft mist inhaler, replaced the Combivent MDI (metered dose inhaler) with HFA propellant, as seen in studies comparing the efficacy and safety of different inhaler types 1, 2. This change occurred after the original CFC-propelled Combivent was phased out due to environmental concerns. The Combivent Respimat delivers the same active ingredients (ipratropium bromide 20 mcg and albuterol sulfate 100 mcg per actuation) but uses a different delivery mechanism that doesn't require propellants. The standard dosing for Combivent Respimat is one inhalation four times daily, not to exceed six inhalations in 24 hours. This soft mist inhaler was designed to provide more efficient drug delivery with a slower-moving mist that's easier to inhale, potentially improving medication deposition in the lungs compared to the previous aerosol version, as supported by a study published in the International Journal of Chronic Obstructive Pulmonary Disease 1. Patients switching from the MDI to Respimat should receive proper instruction on the different technique required for the new device. Key points to consider include:
- The replacement of Combivent MDI with Combivent Respimat due to environmental concerns and the phase-out of CFC-propelled inhalers.
- The equivalent efficacy and safety of Combivent Respimat compared to the MDI version, as demonstrated in clinical trials 2.
- The importance of proper instruction for patients switching to the new Respimat device to ensure effective use and minimize potential issues. Overall, the switch from Combivent MDI to Combivent Respimat aims to maintain or improve patient outcomes while addressing environmental concerns, with studies indicating the Respimat's potential for improved drug delivery and patient satisfaction 1, 2.